Does the media prefer CYTK or TARS?

In the previous week, Cytokinetics had 1 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 16 mentions for Cytokinetics and 15 mentions for Tarsus Pharmaceuticals. Cytokinetics' average media sentiment score of 0.89 beat Tarsus Pharmaceuticals' score of -0.08 indicating that Cytokinetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 8 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tarsus Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TARS or SMMT?

In the previous week, Tarsus Pharmaceuticals had 8 more articles in the media than Summit Therapeutics. MarketBeat recorded 15 mentions for Tarsus Pharmaceuticals and 7 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.59 beat Tarsus Pharmaceuticals' score of -0.08 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Summit Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate RDY or TARS?

Tarsus Pharmaceuticals has a consensus target price of $90.17, indicating a potential upside of 38.49%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Tarsus Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 2.78

Does the media favor RDY or TARS?

In the previous week, Tarsus Pharmaceuticals had 8 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 15 mentions for Tarsus Pharmaceuticals and 7 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.92 beat Tarsus Pharmaceuticals' score of -0.08 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tarsus Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Tarsus Pharmaceuticals (TARS) Competitors

$65.22 -0.12 (-0.18%)

As of 12:38 PM Eastern

Compare

TARS vs. CYTK, SMMT, NUVL, RDY, and CRNX

Should you buy Tarsus Pharmaceuticals stock or one of its competitors? MarketBeat compares Tarsus Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tarsus Pharmaceuticals include Cytokinetics (CYTK), Summit Therapeutics (SMMT), Nuvalent (NUVL), Dr. Reddy's Laboratories (RDY), and Crinetics Pharmaceuticals (CRNX).

How does Tarsus Pharmaceuticals compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 2.6% of Cytokinetics shares are owned by insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cytokinetics has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

Cytokinetics currently has a consensus price target of $100.85, indicating a potential upside of 31.76%. Tarsus Pharmaceuticals has a consensus price target of $90.17, indicating a potential upside of 38.49%. Given Tarsus Pharmaceuticals' higher probable upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

Tarsus Pharmaceuticals has a net margin of -9.02% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

In the previous week, Cytokinetics had 1 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 16 mentions for Cytokinetics and 15 mentions for Tarsus Pharmaceuticals. Cytokinetics' average media sentiment score of 0.89 beat Tarsus Pharmaceuticals' score of -0.08 indicating that Cytokinetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	8 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tarsus Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tarsus Pharmaceuticals has higher revenue and earnings than Cytokinetics. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	108.18	-$784.96M	-$6.84	N/A
Tarsus Pharmaceuticals	$451.36M	6.21	-$66.42M	-$1.14	N/A

Summary

Tarsus Pharmaceuticals beats Cytokinetics on 10 of the 17 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Summit Therapeutics?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

Summit Therapeutics has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Tarsus Pharmaceuticals' return on equity of -14.19% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%
Summit Therapeutics	N/A	-168.94%	-141.92%

In the previous week, Tarsus Pharmaceuticals had 8 more articles in the media than Summit Therapeutics. MarketBeat recorded 15 mentions for Tarsus Pharmaceuticals and 7 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.59 beat Tarsus Pharmaceuticals' score of -0.08 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Summit Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tarsus Pharmaceuticals has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.23, meaning that its share price is 223% less volatile than the broader market.

Tarsus Pharmaceuticals currently has a consensus target price of $90.17, indicating a potential upside of 38.49%. Summit Therapeutics has a consensus target price of $26.15, indicating a potential upside of 88.62%. Given Summit Therapeutics' higher probable upside, analysts plainly believe Summit Therapeutics is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tarsus Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	6.21	-$66.42M	-$1.14	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

Summary

Tarsus Pharmaceuticals beats Summit Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Nuvalent?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Nuvalent (NASDAQ:NUVL) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

Tarsus Pharmaceuticals presently has a consensus price target of $90.17, suggesting a potential upside of 38.49%. Nuvalent has a consensus price target of $127.73, suggesting a potential upside of 3.04%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15

Tarsus Pharmaceuticals has higher revenue and earnings than Nuvalent. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	6.21	-$66.42M	-$1.14	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

Nuvalent has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Tarsus Pharmaceuticals' return on equity of -14.19% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%
Nuvalent	N/A	-40.11%	-35.43%

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are owned by insiders. Comparatively, 5.0% of Nuvalent shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Tarsus Pharmaceuticals had 15 more articles in the media than Nuvalent. MarketBeat recorded 15 mentions for Tarsus Pharmaceuticals and 0 mentions for Nuvalent. Nuvalent's average media sentiment score of 0.00 beat Tarsus Pharmaceuticals' score of -0.08 indicating that Nuvalent is being referred to more favorably in the news media.

Company	Overall Sentiment
Tarsus Pharmaceuticals	Neutral
Nuvalent	Neutral

Tarsus Pharmaceuticals has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, Nuvalent has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market.

Summary

Tarsus Pharmaceuticals beats Nuvalent on 10 of the 15 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Dr. Reddy's Laboratories' return on equity of 9.49% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

In the previous week, Tarsus Pharmaceuticals had 8 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 15 mentions for Tarsus Pharmaceuticals and 7 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.92 beat Tarsus Pharmaceuticals' score of -0.08 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tarsus Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tarsus Pharmaceuticals has a consensus target price of $90.17, indicating a potential upside of 38.49%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

Dr. Reddy's Laboratories has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

Dr. Reddy's Laboratories has higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	2.84	$456M	$0.44	27.69
Tarsus Pharmaceuticals	$451.36M	6.21	-$66.42M	-$1.14	N/A

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Tarsus Pharmaceuticals beats Dr. Reddy's Laboratories on 9 of the 17 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Crinetics Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

Tarsus Pharmaceuticals has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.12, suggesting that its stock price is 88% less volatile than the broader market.

In the previous week, Tarsus Pharmaceuticals had 4 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 15 mentions for Tarsus Pharmaceuticals and 11 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 0.57 beat Tarsus Pharmaceuticals' score of -0.08 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Crinetics Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Tarsus Pharmaceuticals has a net margin of -9.02% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Tarsus Pharmaceuticals' return on equity of -14.19% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

Tarsus Pharmaceuticals has higher revenue and earnings than Crinetics Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	6.21	-$66.42M	-$1.14	N/A
Crinetics Pharmaceuticals	$7.70M	1,155.68	-$465.32M	-$5.04	N/A

Tarsus Pharmaceuticals currently has a consensus price target of $90.17, indicating a potential upside of 38.49%. Crinetics Pharmaceuticals has a consensus price target of $81.00, indicating a potential downside of 3.45%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Tarsus Pharmaceuticals is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are owned by insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Tarsus Pharmaceuticals beats Crinetics Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

Get Tarsus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TARS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TARS vs. The Competition

Export

Metric	Tarsus Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.80B	$11.82B	$6.97B	$13.00B
Dividend Yield	N/A	2.71%	2.59%	9.93%
P/E Ratio	-57.13	789.72	270.82	25.98
Price / Sales	6.21	999.49	668.88	111.42
Price / Cash	N/A	72.59	71.89	50.37
Price / Book	8.05	10.78	13.28	6.24
Net Income	-$66.42M	$2.78B	$3.45B	$342.69M
7 Day Performance	10.27%	3.42%	4.11%	4.24%
1 Month Performance	-7.72%	-1.57%	-2.04%	-1.10%
1 Year Performance	35.78%	192.66%	76.51%	22.19%

Tarsus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TARS Tarsus Pharmaceuticals	3.3051 of 5 stars	$65.11 -0.3%	$90.17 +38.5%	+56.7%	$2.80B	$451.36M	N/A	50	Trending News Earnings Report
CYTK Cytokinetics	3.5229 of 5 stars	$79.35 -1.6%	$99.90 +25.9%	+131.6%	$9.88B	$105.82M	N/A	250	Trending News Earnings Report Analyst Forecast
SMMT Summit Therapeutics	3.7409 of 5 stars	$12.31 -6.0%	$26.15 +112.4%	-52.5%	$9.86B	N/A	N/A	110	Analyst Forecast
NUVL Nuvalent	1.7152 of 5 stars	$123.96 flat	$127.73 +3.0%	N/A	$9.79B	N/A	N/A	40
RDY Dr. Reddy's Laboratories	2.8269 of 5 stars	$11.66 -1.0%	N/A	-9.2%	$9.73B	$331.19B	26.49	27,527

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TARS) was last updated on 8/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tarsus Pharmaceuticals (TARS) Competitors

TARS vs. CYTK, SMMT, NUVL, RDY, and CRNX

How does Tarsus Pharmaceuticals compare to Cytokinetics?

Summary

How does Tarsus Pharmaceuticals compare to Summit Therapeutics?

Summary

How does Tarsus Pharmaceuticals compare to Nuvalent?

Summary

How does Tarsus Pharmaceuticals compare to Dr. Reddy's Laboratories?

Summary

How does Tarsus Pharmaceuticals compare to Crinetics Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARS vs. The Competition

Tarsus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tarsus Pharmaceuticals (TARS) Competitors

TARS vs. CYTK, SMMT, NUVL, RDY, and CRNX

How does Tarsus Pharmaceuticals compare to Cytokinetics?

Do insiders and institutionals have more ownership in CYTK or TARS?

Which has more risk & volatility, CYTK or TARS?

Do analysts recommend CYTK or TARS?

Is CYTK or TARS more profitable?

Does the media prefer CYTK or TARS?

Which has better earnings and valuation, CYTK or TARS?

Summary

How does Tarsus Pharmaceuticals compare to Summit Therapeutics?

Is TARS or SMMT more profitable?

Does the media refer more to TARS or SMMT?

Which has more volatility and risk, TARS or SMMT?

Do analysts rate TARS or SMMT?

Do insiders and institutionals believe in TARS or SMMT?

Which has stronger valuation and earnings, TARS or SMMT?

Summary

How does Tarsus Pharmaceuticals compare to Nuvalent?

Do analysts prefer TARS or NUVL?

Which has better valuation and earnings, TARS or NUVL?

Is TARS or NUVL more profitable?

Do institutionals & insiders hold more shares of TARS or NUVL?

Does the media prefer TARS or NUVL?

Which has more volatility and risk, TARS or NUVL?

Summary

How does Tarsus Pharmaceuticals compare to Dr. Reddy's Laboratories?

Is RDY or TARS more profitable?

Does the media favor RDY or TARS?

Do analysts rate RDY or TARS?

Which has more volatility & risk, RDY or TARS?

Which has stronger valuation and earnings, RDY or TARS?

Do institutionals & insiders have more ownership in RDY or TARS?

Summary

How does Tarsus Pharmaceuticals compare to Crinetics Pharmaceuticals?

Which has more risk & volatility, TARS or CRNX?

Does the media refer more to TARS or CRNX?

Is TARS or CRNX more profitable?

Which has better valuation and earnings, TARS or CRNX?

Do analysts prefer TARS or CRNX?

Do insiders & institutionals believe in TARS or CRNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARS vs. The Competition

Tarsus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools